Total Payments
$1,877
2024 Payments
$19.19
Companies
18
Transactions
39
Medicare Patients
2,074
Medicare Billing
$226,965
Payment Breakdown by Category
Food & Beverage$1,597 (85.1%)
Education$280.18 (14.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,597 | 28 | 85.1% |
| Education | $280.18 | 11 | 14.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $284.39 | 5 | $0 (2023) |
| Celgene Corporation | $203.72 | 3 | $0 (2018) |
| PFIZER INC. | $173.89 | 3 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $164.86 | 2 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $147.36 | 3 | $0 (2022) |
| TESARO, Inc. | $136.19 | 5 | $0 (2019) |
| GlaxoSmithKline, LLC. | $132.76 | 2 | $0 (2021) |
| Heron Therapeutics, Inc. | $128.98 | 2 | $0 (2017) |
| Janssen Scientific Affairs, LLC | $114.27 | 1 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $105.60 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $19.19 | 1 | Tempus AI, Inc ($19.19) |
| 2023 | $32.06 | 2 | E.R. Squibb & Sons, L.L.C. ($16.57) |
| 2022 | $172.15 | 3 | AstraZeneca Pharmaceuticals LP ($128.35) |
| 2021 | $191.94 | 6 | GlaxoSmithKline, LLC. ($115.00) |
| 2020 | $12.45 | 1 | Karyopharm Therapeutics Inc. ($12.45) |
| 2019 | $411.09 | 6 | Amgen Inc. ($124.99) |
| 2018 | $544.72 | 11 | TESARO, Inc. ($118.86) |
| 2017 | $493.08 | 9 | Amgen Inc. ($143.91) |
All Payment Transactions
39 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/16/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $19.19 | General |
| 08/31/2023 | Amgen Inc. | — | Education | In-kind items and services | $15.49 | General |
| 06/20/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | In-kind items and services | $16.57 | General |
| Category: Oncology | ||||||
| 10/11/2022 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $61.88 | General |
| Category: Oncology | ||||||
| 06/30/2022 | EMD Serono, Inc. | — | Education | In-kind items and services | $43.80 | General |
| 02/23/2022 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $66.47 | General |
| Category: Oncology | ||||||
| 12/01/2021 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $115.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $22.56 | General |
| 11/01/2021 | AstraZeneca Pharmaceuticals LP | — | Education | In-kind items and services | $19.01 | General |
| 08/26/2021 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 06/15/2021 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Education | In-kind items and services | $11.07 | General |
| Category: Hematology | ||||||
| 05/27/2021 | Epizyme, Inc., | TAZVERIK (Drug) | Education | In-kind items and services | $11.50 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2020 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Education | In-kind items and services | $12.45 | General |
| Category: Oncology | ||||||
| 12/18/2019 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $17.76 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $83.15 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2019 | TESARO, Inc. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2019 | PFIZER INC. | TALZENNA (Drug) | Food and Beverage | In-kind items and services | $89.90 | General |
| Category: ONCOLOGY | ||||||
| 04/23/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $77.96 | General |
| Category: Oncology | ||||||
| 03/12/2019 | Amgen Inc. | Vectibix (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Oncology | ||||||
| 12/12/2018 | TESARO, Inc. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $22.57 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2018 | Janssen Scientific Affairs, LLC | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $114.27 | General |
| Category: Oncology | ||||||
| 09/20/2018 | TESARO, Inc. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $15.49 | General |
| Category: ONCOLOGY | ||||||
| 09/20/2018 | TESARO, Inc. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $1.45 | General |
| Category: ONCOLOGY | ||||||
| 07/30/2018 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $71.19 | General |
| Category: ONCOLOGY | ||||||
| 05/24/2018 | TESARO, Inc. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $79.35 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 354 | 638 | $133,270 | $49,390 |
| 2022 | 7 | 446 | 714 | $152,409 | $56,276 |
| 2021 | 9 | 653 | 916 | $151,466 | $73,818 |
| 2020 | 8 | 621 | 787 | $85,276 | $47,481 |
Total Patients
2,074
Total Services
3,055
Medicare Billing
$226,965
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 167 | 408 | $80,784 | $29,468 | 36.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 62 | 98 | $26,950 | $10,881 | 40.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 85 | 92 | $12,696 | $4,558 | 35.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 20 | 20 | $6,760 | $2,483 | 36.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 20 | 20 | $6,080 | $2,000 | 32.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 179 | 388 | $76,824 | $27,616 | 35.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 61 | 107 | $29,425 | $11,565 | 39.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 42 | 42 | $14,196 | $5,921 | 41.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 113 | 121 | $16,698 | $5,693 | 34.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 25 | 27 | $8,208 | $2,818 | 34.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 11 | $4,466 | $1,677 | 37.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 18 | $2,592 | $985.26 | 38.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 133 | 270 | $45,387 | $22,298 | 49.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 94 | 188 | $24,000 | $12,775 | 53.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 115 | 122 | $14,200 | $6,897 | 48.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 46 | 55 | $12,784 | $6,713 | 52.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 40 | 48 | $8,861 | $5,231 | 59.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 27 | 27 | $7,776 | $4,138 | 53.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 35 | 35 | $10,640 | $3,768 | 35.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 21 | 21 | $5,357 | $2,919 | 54.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 79 | 83 | $6,862 | $2,896 | 42.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 17 | 17 | $6,902 | $2,583 | 37.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 20 | 23 | $3,312 | $1,310 | 39.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 15 | 16 | $3,232 | $1,309 | 40.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 11 | 11 | $2,153 | $979.83 | 45.5% |
About Dr. Daniel Danso, MD
Dr. Daniel Danso, MD is a Hematology & Oncology healthcare provider based in Midland, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/13/2005. The National Provider Identifier (NPI) number assigned to this provider is 1386639680.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Danso, MD has received a total of $1,877 in payments from pharmaceutical and medical device companies, with $19.19 received in 2024. These payments were reported across 39 transactions from 18 companies. The most common payment nature is "Food and Beverage" ($1,597).
As a Medicare-enrolled provider, Danso has provided services to 2,074 Medicare beneficiaries, totaling 3,055 services with total Medicare billing of $226,965. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Midland, MI
- Active Since 09/13/2005
- Last Updated 10/13/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1386639680
Products in Payments
- ZEJULA (Drug) $268.95
- KEYTRUDA (Biological) $164.86
- SUSTOL (Drug) $128.98
- Abraxane (Drug) $124.99
- Vectibix (Biological) $124.99
- DARZALEX (Biological) $114.27
- OPDIVO (Biological) $94.53
- TALZENNA (Drug) $89.90
- IBRANCE (Drug) $83.99
- Revlimid (Drug) $78.73
- LYNPARZA (Drug) $66.47
- IMFINZI (Biological) $61.88
- GILOTRIF (Drug) $40.91
- Neulasta (Biological) $16.93
- XPOVIO (Drug) $12.45
- TAZVERIK (Drug) $11.50
- Pomalyst (Drug) $11.07
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Midland
Dr. Santiago Moscoso Martinez, M.d, M.D
Hematology & Oncology — Payments: $7,343
Hematology & Oncology $7,343
Amruth Palla, M.d, M.D
Hematology & Oncology — Payments: $2,897
Hematology & Oncology $2,897
Ahmed Abdel-Maksoud, Md, MD
Hematology & Oncology — Payments: $1,417
Hematology & Oncology $1,417
Sharon Levandowski, Md, MD
Hematology & Oncology — Payments: $703.87
Hematology & Oncology $703.87
Dr. Ashutosh Rastogi, Md, MD
Hematology & Oncology — Payments: $210.84
Hematology & Oncology $210.84